Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation


Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
To determine the clinical effectiveness, safety and cost-effectiveness of omalizumab, as an add-on therapy to standard care, within its licensed indication, compared with standard therapy alone for the treatment of severe persistent allergic asthma in adults and adolescents aged 12 years and children aged 6-11 years.

Authors' conclusions
Omalizumab reduces the incidence of CS exacerbations in adults and children, with benefits on other outcomes in adults. Limited, underpowered subgroup evidence exists that omalizumab reduces exacerbations and OCS requirements in adults on OCSs. Evidence in children is weaker and more uncertain. The ICERs are above conventional NHS thresholds of cost-effectiveness. The key drivers of cost-effectiveness are asthma-related mortality risk and, to a lesser extent, HRQoL improvement and OCS-related adverse effects. An adequately powered double-blind RCT in both adults and children on maintenance OCSs and an individual patient data meta-analysis of existing trials should be considered. A registry of all patients on omalizumab should be established.

Project page URL
http://www.hta.ac.uk/2657

Final publication URL
http://www.journalslibrary.nihr.ac.uk/hta/volume-17/issue-52

URL for DARE abstract
http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?AccessionNumber=12013068148& UserID=0

Link to NHS EED abstract
http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?AccessionNumber=22013052646& UserID=0

Indexing Status
Subject indexing assigned by CRD

MeSH
Anti-Allergic Agents; Anti-Asthmatic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Asthmas

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

**Address for correspondence**
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

**AccessionNumber**
32011001617

**Date abstract record published**
14/12/2011